Genetically proxied ADRB1 inhibition was associated with lower risk of coronary artery disease (per 1 mm Hg lower SBP: OR 0.95, 95% CI 0.92 to 0.98; P = 1.5 × 10−3) and weakly associated with risk of stroke (OR 1.03, 95% CI 0.99 to 1.07; P = 0.18). Here, ADRB1 is linked to stroke disorder.